Last updated 2026-07-20
Portfolio
0
in our dataset
Rounds participated
0
Rounds led
0
Rounds' value
—
total disclosed, rounds participated
Stages
—
About
Professor Yechezkel Barenholz is a Professor of Biochemistry at the Hebrew University-Hadassah Medical School in Jerusalem, Israel. He is a world-renowned expert in drug delivery systems and nanotechnology, best known as a key inventor of Doxil, the first FDA-approved nano-drug for cancer treatment. He has co-invented over 55 granted patents and founded six Israeli medical startups: NasVax (now Therapix), Moebius Medical, PolyPid, LipoCureRx, Ayana Pharma, and Re-BioticR. His research focuses on the development of liposome-based nanomedicines for treating cancer, inflammatory and autoimmune diseases, bacterial infections, and osteoarthritis.
Portfolio
No portfolio companies in this dataset yet.
Investment activity
Portfolio by sector
Health Tech & Life Sciences2
Q&A
- What is Yechezkel Barenholz's primary investment focus by sector?
- Yechezkel Barenholz primarily focuses on the Health Tech & Life Sciences sector, with all of his known portfolio companies operating within this area.
- Can you name some of Yechezkel Barenholz's portfolio companies?
- Yechezkel Barenholz's portfolio includes Ayana Pharma, which develops liposomal drugs for cancer treatment, and LipoCure, focused on liposome-based nano drugs.
- When did Yechezkel Barenholz make his most recent disclosed investment?
- Yechezkel Barenholz's most recent disclosed investment occurred in September 2017.
- What was the funding stage and amount for LipoCure?
- LipoCure secured an $8M A Round investment, with Yechezkel Barenholz participating.
- What kind of companies does Ayana Pharma develop?
- Ayana Pharma, a portfolio company of Yechezkel Barenholz, develops liposomal drugs for cancer treatment.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Radar intelligence
Patents
| EPO | 47 |
|---|